Background/Objectives: The aim of this study was to demonstrate the importance of 68Gallium (68Ga)–prostate specific membrane antigen (PSMA)–positron emissions tomography (PET)/computed tomography (CT)(PET/CT) in prostate cancer patients for therapy management with individual analyses regarding the Gleason score, prostate specific antigen (PSA) value, and the risk groups defined by D’Amico. This evidence concerns the gene KLK3 and prostate carcinoma.